Stockscreener 앱 받기
4.93
3.57%
0.17
시간 외 거래:
4.93
전일 마감가:
$4.76
열려 있는:
$4.78
하루 거래량:
76,267
Relative Volume:
0.11
시가총액:
$29.04M
수익:
$14.58M
순이익/손실:
$-12.57M
주가수익비율:
-0.868
EPS:
-5.68
순현금흐름:
$-13.07M
1주 성능:
+10.54%
1개월 성능:
+11.29%
6개월 성능:
+19.95%
1년 성능:
+141.68%
1일 변동 폭
$4.70
$5.0199
1주일 범위
$4.10
$5.6899
52주 변동 폭
$1.98
$7.95
비보스 테라퓨틱스 Stock (VVOS) Company Profile
명칭
Vivos Therapeutics Inc
전화
(866)908-4867
주소
7921 SOUTHPARK PLAZA,, LITTLETON
VVOS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VVOS
Vivos Therapeutics Inc
|
4.93 | 30.51M | 14.58M | -12.57M | -13.07M | -5.68 |
|
ABT
Abbott Laboratories
|
130.69 | 221.54B | 43.11B | 13.98B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
104.83 | 156.19B | 18.49B | 2.51B | 2.72B | 1.68 |
|
SYK
Stryker Corp
|
380.86 | 144.43B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
89.67 | 114.47B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
79.24 | 46.53B | 5.69B | 4.15B | 623.10M | 6.95 |
비보스 테라퓨틱스 주식(VVOS)의 최신 뉴스
Applying Elliott Wave Theory to Vivos Therapeutics Inc.Conservative Asset Allocation Risk Analysis - Newser
Vivos Therapeutics (NASDAQ:VVOS) Upgraded at Wall Street Zen - Defense World
Visual trend scoring systems applied to Vivos Therapeutics Inc.Investment Life Cycle Planning Summary - Newser
Relief Rally in Vivos Therapeutics Inc. Stock — Can It HoldEntry Plan for Oversold Reversal Stocks Released - metal.it
Is Vivos Therapeutics Inc. stock poised for growthForecast Model for Intraday Buy Signals - Newser
Can you recover from losses in Vivos Therapeutics Inc.Trend Reversal Watch with Entry Signals - Newser
What is the dividend policy of Vivos Therapeutics Inc. stockConsistent triple returns - Jammu Links News
Vivos Therapeutics Inc. Stock Analysis and ForecastRapid wealth multiplication - Jammu Links News
What are the latest earnings results for Vivos Therapeutics Inc.Discover stocks with massive upside potential - Jammu Links News
What catalysts could drive Vivos Therapeutics Inc. stock higher in 2025Capitalize on market trends with confidence - Jammu Links News
Is Vivos Therapeutics Inc. stock overvalued or undervaluedAchieve breakthrough financial results today - Jammu Links News
What is the risk reward ratio of investing in Vivos Therapeutics Inc. stockDiscover breakthrough investment opportunities - Jammu Links News
Why is Vivos Therapeutics Inc. stock attracting strong analyst attentionUnlock expert market analysis instantly - Jammu Links News
Should I hold or sell Vivos Therapeutics Inc. stock in 2025Capitalize on trading strategies that deliver - Jammu Links News
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Short Interest Update - Defense World
How volatile is Vivos Therapeutics Inc. stock compared to the marketMaximize gains with expert trading strategies - Jammu Links News
Is Vivos Therapeutics Inc. meeting your algorithmic filter criteriaFree Fast Return Equity Trade Forecast - Newser
Detecting price anomalies in Vivos Therapeutics Inc. with AIStable Profit Zone and Loss Control Analysis - Newser
Is Vivos Therapeutics Inc. reversing from oversold territoryShort-Term Support and Resistance Forecast - Newser
Should you hold or exit Vivos Therapeutics Inc. nowNeural Network Based Equity Prediction System - Newser
What makes Vivos Therapeutics Inc. stock price move sharplyWeekly Stock Movement Prediction Watchlist - Newser
Short interest data insights for Vivos Therapeutics Inc.Capital Growth Plan for New Investors - Newser
Can momentum traders help lift Vivos Therapeutics Inc.Earnings Report Summary with Market Impact - Newser
Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Shares Climb 43% But Its Business Is Yet to Catch Up - 富途牛牛
Opera Limited shares rise 1.56% premarket after recent executive appointments at Vivos Therapeutics, Inc. - AInvest
How Efficient Is Vivos Therapeutics Inc. at Controlling Operating CostsFree Trade Timing Strategy With Technical Data - Newser
Vivos Therapeutics Adds to Management Team to Support Expansion and Growth - GlobeNewswire
Vivos Therapeutics appoints two executives to support growth strategy - Investing.com Australia
Vivos Therapeutics appoints two executives to support growth strategy By Investing.com - Investing.com UK
How Interest Rate Changes Impact Vivos Therapeutics Inc. Stock PerformanceAsset Safety Selection Using Quantitative Analysis - Newser
Published on: 2025-07-29 06:26:38 - Newser
Vivos Therapeutics Inc. Stock Recovery Path — Analyst BreakdownLow Capital High Return Stock Plans Reviewed - beatles.ru
What is Vivos Therapeutics Inc. company’s growth strategyFree Wealth Planning Blueprint - Jammu Links News
비보스 테라퓨틱스 (VVOS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.35%
0.14%
자본화:
|
볼륨(24시간):